MG
AVBP icon

Michael Gelband’s ArriVent BioPharma AVBP Stock Holding History

Michael Gelband’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-19,025
Closed -$439K – 2159
2026
Q1 		$439K Sell
19,025
-41,104
-68% -$928K ﹤0.01% 1225
2025
Q4 		$1.21M Buy
60,129
+23,993
+66% +$499K 0.01% 922
2025
Q3 		$667K Sell
36,136
-11,449
-24% -$225K 0.01% 1098
2025
Q2 		$1.04M Buy
47,585
+25,317
+114% +$526K 0.01% 953
2025
Q1 		$412K Buy
+22,268
New +$545K ﹤0.01% 1156

Other funds holding AVBP

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Michael Gelband's AVBP Position: Q2 2026 in Review

Michael Gelband sold out of ArriVent BioPharma (AVBP) in Q2 2026, closing a stake of 19,025 shares — an estimated $439K sold.

Michael Gelband first reported a position in AVBP in Q1 2025 and held it in 5 quarters. The position peaked at $1.21M in Q4 2025. 156 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • Michael Gelband reported no remaining ArriVent BioPharma position as of Q2 2026 after selling out during the quarter.
  • Michael Gelband sold 19,025 ArriVent BioPharma shares in Q2 2026, an estimated $439K.
  • Michael Gelband first reported a position in ArriVent BioPharma in Q1 2025 and held it in 5 quarters.
  • Michael Gelband's ArriVent BioPharma position peaked at $1.21M in Q4 2025.
  • 156 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.